The relationship between leukemia and TP53 gene codon Arg72Pro polymorphism: analysis in a multi-ethnic population

Papers of special note have been highlighted as: • of interest;

Reference

• 1. Estey EH. Prognostic factors in acute myelogenous leukemia. Leukemia 15(4), 670–672 (2001).
  Medline CASGoogle Scholar
• 2. Satoh Y, Matsumura I, Tanaka H et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia 26 (2), 303–311 (2012). • Provides an overview required for multi-step leukemogenesis and the genomic instability caused by impaired Gadd45a function.
  Medline CASGoogle Scholar
• 3. Drokow EK, Sun K, Ahmed HA, Akpabla GS, Song J, Shi M. Circulating microRNA as diagnostic biomarkers for haematological cancers: a systematic review and meta-analysis. Cancer Manag. Res. 11, 4313 (2019).
  Medline CASGoogle Scholar
• 4. Li SY, Ye JY, Liang EY, Zhou LX, Yang M. Association between MTHFR C677T polymorphism and risk of acute lymphoblastic leukemia: a meta-analysis based on 51 case-control studies. Med. Sci. Monit. 21, 740 (2015).
  Medline CASGoogle Scholar
• 5. Chen J, Liu Y, Cai QQ et al. Type D personality parents of children with leukemia tend to experience anxiety: the mediating effects of social support and coping style. Medicine 94.10 (2015).
  Google Scholar
• 6. Kowalczyk J, Nurzynska-Flak J, Armata J et al. Incidence and clinical characteristics of second malignant neoplasms in children: a multicenter study of a polish pediatric leukemia/lymphoma group. Med Sci. Monit. 10(3), CR117–CR122 (2004).
  MedlineGoogle Scholar
• 7. Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5), 937–951 (2009).
  Medline CASGoogle Scholar
• 8. Ma Z, Morris SW, Valentine V et al. Fusion of two novel genes, RBM15 and MKL1, in the t (1; 22) (p13; q13) of acute megakaryoblastic leukemia. Nat. Genet. 28(3), 220–221 (2001).
  Medline CASGoogle Scholar
• 9. Weng Y, Lu L, Yuan G et al. p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. PLoS ONE 7(9), e45820 (2012).
  Medline CASGoogle Scholar
• 10. Descatha A, Jenabian A, Conso F, Ameille J. Occupational exposures and haematological malignancies: overview on human recent data. Cancer Causes Control 16(8), 939–953 (2005).
  MedlineGoogle Scholar
• 11. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9(10), 701–713 (2009).
  Medline CASGoogle Scholar
• 12. Hainaut P, Wiman KG. 30 years and a long way into p53 research. Lancet Oncol. 10 (9), 913–919 (2009). • Discusses the progress and understanding of p53 from obscure oncogene to key tumor-suppressor gene with clinical potential.
  MedlineGoogle Scholar
• 13. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case–control studies. Int. J. Cancer 129(4), 920–930 (2011).
  Medline CASGoogle Scholar
• 14. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germline transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome. Nature 348 (6303), 747–749.
  MedlineGoogle Scholar
• 15. Barbosa K, Li S, Adams PD, Deshpande AJ. The role of TP53 in acute myeloid leukemia: challenges and opportunities. Genes Chromosomes Cancer 58 (12), 875–888 (2019). • This review suggested the use of pharmacological activators of TP53 and it clinical benefit in acute myeloid leukaemia.
  Medline CASGoogle Scholar
• 16. Malkin D, Nichols KE, Zelley K, Schiffman JD. Predisposition to pediatric and hematologic cancers: a moving target. Am. Soc. Clin. Oncol. Educ. B 34(1), e44–e55 (2014).
  Google Scholar
• 17. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia the cancer genome atlas research network. N. Engl. J. Med. 368(22), 2059–2074 (2013).
  MedlineGoogle Scholar
• 18. Papaemmanuil E, Gerstung M, Bullinger L et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374(23), 2209–2221 (2016).
  Medline CASGoogle Scholar
• 19. Quintás-Cardama A, Hu C, Qutub A et al. P53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia 31(6), 1296–1305 (2017).
  Medline CASGoogle Scholar
• 20. Welch JS, Petti AA, Miller CA et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N. Engl. J. Med. 375(21), 2023–2036 (2016).
  Medline CASGoogle Scholar
• 21. Pant V, Quintás-Cardama A, Lozano G. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood 120(26), 5118–5127 (2012).
  Medline CASGoogle Scholar
• 22. Stoddart A, Fernald AA, Wang J et al. Haploinsufficiency of del (5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood 123(7), 1069–1078 (2014).
  Medline CASGoogle Scholar
• 23. McGraw KL, Zhang LM, Rollison DE et al. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 5(3), e291–e291 (2015).
  Medline CASGoogle Scholar
• 24. McGraw KL, Cluzeau T, Sallman DA et al. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del (5q) myelodysplastic syndromes. Oncotarget 6(33), 34437 (2015). • A useful research article discussing the role of TP53 in preleukemia conditions.
  MedlineGoogle Scholar
• 25. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer 108(2), 196–199 (2004).
  Medline CASGoogle Scholar
• 26. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 18(16), 4961 (1990).
  Medline CASGoogle Scholar
• 27. Bergamaschi G, Merante S, Orlandi E, Galli A, Bernasconi P, Cazzola M. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 89(7), 868–869 (2004).
  Medline CASGoogle Scholar
• 28. Ruan XL, Li S, Zeng XT, Xia LH, Hu Y. No association between cytochrome P450 2D6 gene polymorphism and risk of acute leukemia: evidence based on a meta- analysis. Chin. Med. J. (Engl.) 126(), 3750–3753 (2013).
  MedlineGoogle Scholar
• 29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta- analysis detected by a simple, graphical test. BMJ 315(7109), 629–634 (1997).
  Medline CASGoogle Scholar
• 30. Martorell-Marugan J, Toro-Dominguez D, Alarcon-Riquelme ME, Carmona-Saez P. MetaGenyo: a web tool for meta-analysis of genetic association studies. BMC Bioinformatics 18(1), 563 (2017).
  MedlineGoogle Scholar
• 31. Schulz E, Lind K, Renner W et al. The TP53 Pro72Arg SNP in de novo acute myeloid leukemia – results of two cohort studies involving 215 patients and 3759 controls. Br. J. Haematol. 181(1), 148 (2018).
  Medline CASGoogle Scholar
• 32. El-Danasouri NM, Ragab SH, Rasheed MA, El_Saadany ZA, Abd El-Fattah SN. MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study. Ann. Clin. Lab. Sci. 44(4), 449–454 (2014).
  Medline CASGoogle Scholar
• 33. de Lourdes Perim A, Guembarovski RL, Oda JM et al. CXCL12 and TP53 genetic polymorphisms as markers of susceptibility in a Brazilian children population with acute lymphoblastic leukemia (ALL). Mol. Biol. Rep. 40 (7), 4591–4596 (2013).
  MedlineGoogle Scholar
• 34. Chen J, Zhu B, Chen J, Li Y. Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population. DNA Cell Biol. 32 (7), 414–419 (2013).
  Medline CASGoogle Scholar
• 35. Chauhan PS, Ihsan R, Mishra AK et al. High order interactions of xenobiotic metabolising genes and P53 codon 72 polymorphisms in acute leukemia. Environ. Mol. Mutagen. 53(8), 619–630 (2012).
  Medline CASGoogle Scholar
• 36. Shi JY, Ren ZH, Jiao B et al. Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia. Int. J. Cancer 128(1), 233–238 (2011).
  Medline CASGoogle Scholar
• 37. Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet. Cytogenet. 195(1), 31–36 (2009).
  Medline CASGoogle Scholar
• 38. Xiong X, Wang M, Wang L et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk. Res. 33(11), 1454–1458 (2009).
  Medline CASGoogle Scholar
• 39. Phang BH, Linn YC, Li H, Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukemia patients. Eur. J. Cancer 44(5), 760–766 (2008).
  Medline CASGoogle Scholar
• 40. Ellis NA, Hou D, Yildiz O et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 112(3), 741–749 (2008).
  Medline CASGoogle Scholar
• 41. Kochethu G, Delgado J, Pepper C et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukemia. Leuk. Res. 30(9), 1113–1118 (2006).
  Medline CASGoogle Scholar
• 42. Takeuchi S, Matsushita M, Tsukasaki K et al. P53 codon 72 polymorphism is associated with disease progression in adult T-cell leukemia/lymphoma. Br. J. Haematol. 131(4), 552–553 (2005).
  Medline CASGoogle Scholar
• 43. Nakano Y, Naoe T, Kiyoi H et al. Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. Leuk. Res. 24(4), 349–352 (2000).
  Medline CASGoogle Scholar
• 44. Legrand F, Renneville A, Macintyre E et al. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new Insights based on a survey of 44 cases. Medicine 92(5), 273–284 (2013).
  MedlineGoogle Scholar
• 45. Donehower LA, Harvey M, Slagle BL et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356(6366), 215–221 (1992).
  Medline CASGoogle Scholar
• 46. Ruan XL, Li S, Meng XY, Geng P, Gao QP, Ao XB. The role of TP53 gene codon 72 polymorphism in leukemia: a PRISMA-compliant systematic review and meta-analysis. Medicine 94(38), e1588 (2015).
  Medline CASGoogle Scholar
• 47. Tian X, Dai S, Sun J, Jiang Y. Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies. Sci. Rep. 6(1), 24097 (2016).
  Medline CASGoogle Scholar
• 48. Wang F, Wang P, Wang B et al. Association between TP53 Arg72Pro polymorphism and thyroid carcinoma risk. Tumor Biol. 35(3), 2723–2728 (2014).
  Medline CASGoogle Scholar
• 49. Tian X, Dai S, Sun J, Jiang S, Jiang Y. The association between the TP53 Arg72Pro polymorphism and colorectal cancer: an updated meta-analysis based on 32 studies. Oncotarget. 8(1), 1156–1165 (2017).
  MedlineGoogle Scholar
• 50. Zorić A, Horvat A, Balija M, Slade N. The Arg72Pro polymorphism of TP53 in Croatian population. Croat. Chem. Acta 85 (2), 239–243 (2012).
  CASGoogle Scholar
• 51. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33(3), 357–365 (2003).
  Medline CASGoogle Scholar
• 52. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 19(2), 1092–1100 (1992).
  Google Scholar
• 53. Boyd SD, Tsai KY, Jacks T. An intact HDM2 RING- finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2(9), 563–568 (2000).
  Medline CASGoogle Scholar
• 54. Preudhomme C, Fenaux P. The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Br. J. Haematol. 98(3), 502–511 (1997).
  Medline CASGoogle Scholar
• 55. Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21(21), 3475–3495 (2002).
  Medline CASGoogle Scholar